AbbVie Inc (NYSE:ABBV)

Monday’s trading has closed, but ABBV is being traded in the after-hours session. After-Hours quote »
67.78
Data as of 4:00pm ET
 +0.42 / +0.62%
Today’s Change
45.50
Today|||52-Week Range
68.06
+28.35%
Year-to-Date
Sanofi's (SNY) Cerdelga a Step Closer to European Approval - Analyst Blog
5:19pm / Zacks.com
Stocks 20 Billionaires Loved and Hated in the Third Quarter
Nov 17 / TheStreet.com
3 Biotech Stocks That Could Soar Even Higher
3:45pm / MotleyFool.com
3 Stocks Moving The Drugs Industry Upward
Nov 17 / TheStreet.com
Low Interest Rates, Gas Prices to Fuel Stock Market Gains in 2015
2:41pm / TheStreet.com
Cramer: Pfizer Deal With Merck Leaves AstraZeneca In the Cold
Nov 17 / TheStreet.com
Today AbbVie (ABBV) Hits New Lifetime High
10:08am / TheStreet.com
Stocks Hitting 52-Week Highs
Nov 17 / Benzinga
Notable Analyst Rating Changes 11/7: (CA) (GNC) (SPLK) Upgraded; (OXY) (ABBV) (SLXP) ...
Nov 23 / Investing Channel
Why Top Dividend Stock Johnson & Johnson Could Plunge in 2015
Nov 17 / MotleyFool.com
George Soros Just Bought These 3 Stocks: Should You?
Nov 23 / MotleyFool.com
7 Biggest Health Problems Americans Face
Nov 16 / MotleyFool.com
Can New Launches Offset Sanofi's Soft Diabetes Business? - Analyst Blog
Nov 21 / Zacks.com
AbbVie Inc. vs. Pfizer Inc.: Which Is the Better Dividend Stock?
Nov 16 / MotleyFool.com
Amgen and AbbVie Strengthen Manufacturing Facilities in Asia - Analyst Blog
Nov 21 / Zacks.com
Where Will Google Stock Be in 10 Years?
Nov 14 / MotleyFool.com
Buy Gilead Sciences
Nov 21 / TheStreet.com
Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Nov 12 / Zacks.com
J&J Seeks FDA Approval for Schizophrenia Treatment - Analyst Blog
Nov 20 / Zacks.com
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Nov 12 / Zacks.com
Shire to Relocate Employees Under One Shire Program - Analyst Blog
Nov 20 / Zacks.com
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bank...
Nov 12 / Zacks.com
Gilead Gains on Harvoni's EU Approval for HCV Treatment - Analyst Blog
Nov 19 / Zacks.com
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Nov 11 / Zacks.com
AstraZeneca Targets More than $45B in Revenues in 2023 - Analyst Blog
Nov 19 / Zacks.com
Stock Market News for November 11, 2014 - Market News
Nov 11 / Zacks.com
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Nov 19 / Zacks.com
Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog
Nov 10 / Zacks.com
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Nov 19 / Zacks.com
Merck Reports Interim Data on Hepatitis C Virus Drug - Analyst Blog
Nov 10 / Zacks.com
Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in th...
Nov 19 / Zacks.com
Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog
Nov 10 / Zacks.com
Celldex Therapeutics Surges on Positive Rindopepimut Data - Analyst Blog
Nov 18 / Zacks.com
Bets gone awry push Paulson fund to loss
Nov 10 / FT.com
Roche's (RHHBY) Avastin Label Expansion Approved by FDA - Analyst Blog
Nov 18 / Zacks.com
Bill Ackman wins Allergan insider trading lawsuit
Nov 04 / FT.com
Novartis Presents Data on Heart Failure Candidate LCZ696 - Analyst Blog
Nov 18 / Zacks.com
Aggressive tax avoidance troubles large investors
Nov 02 / FT.com
Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Nov 17 / Zacks.com
Pfizer chief: tax inversions still have "meaningful value"
Oct 28 / FT.com
Jim Cramer Answers Twitter (TWTR) Questions on Gold, Gilead and More
Nov 17 / TheStreet.com
The Silver Economy: Silicon Valley joins quest to 'cure' ageing
Oct 26 / FT.com

To view my watchlist

Not a member yet?

Sign up now for a free account

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2014 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2014. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2014 and/or its affiliates.